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Psychology and the enhancement of medication adherence 
Abstract 
This paper reports on a new approach to the enhancement of medication adherence - Medication 
Alliance. Medication Alliance was developed and piloted by a project team that includes Mitch Byrne as 
project leader, Frank Deane as research supervisor, and two consultants, Tim Coombs and Gordon 
Lambert. Because Medication Alliance borrows heavily from psychological principles such as functional 
analysis and cognitive therapy, this presentation is entitled 'Psychology and the Enhancement of 
Medication Adherence '. However, Medication Alliance is a non-discipline specific therapy approach that 
fits well within the purview of any clinician delivering psychosocial interventions. The theoretical 
underpinnings of the various Health Beliefs models and the importance of the Therapeutic Alliance in 
treatment outcomes shapes Medication Alliance as a contemporary intervention for an enduring problem 
in the effective delivery of mental health services. 
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Psychology And The Enhancement Of Medication Adherence. 
Introduction 
This paper reports on a new approach to the enhancement of medication adherence - Medication 
Alliance. Medication Alliance was developed and piloted by a project team that includes Mitch Byrne 
as project leader, Frank Deane as research supervisor, and two consultants, Tim Coombs and Gordon 
Lambert. Because Medication Alliance borrows heavily from psychological principles such as 
functional analysis and cognitive therapy, this presentation is entitled 'Psychology and the 
Enhancement of Medication Adherence '. However, Medication Alliance is a non-discipline specific 
therapy approach that fits well within the purview of any clinician delivering psychosocial 
interventions. The theoretical underpinnings of the various Health Beliefs models and the importance 
of the Therapeutic Alliance in treatment outcomes shapes Medication Alliance as a contemporary 
intervention for an enduring problem in the effective delivery of mental health services. 
The impact of non adherence 
Severe mental health problems are a major cause of human misery for a substantial proportion ofthe 
popUlation. In schizophrenia, for instance, the lifetime prevalence may be as high as 1.5% (Sue et aI., 
2000). Schizophrenia is a chronic relapsing condition, with 80% of those having one episode of illness 
going on to experience future mental ill health. Further to this, people who experience schizophrenic 
illnesses have on average significantly poorer physical health and a reduced life expectancy. In addition 
to the impact on the sufferer and their family, schizophrenia imposes a substantial economic impact 
upon the community. 
Fortunately, the health system has responded to the challenge of schizophrenia and other psychotic 
disorders with the development of a range of effective treatment strategies. While non-pharmaceutical 
approaches to treatment and rehabilitation have proven promising over recent times, medication 
remains the primary tool in the clinician's arsenal. Recently the so-called 'atypical' antipsychotic 
medications have been developed and the efficacy ofthese medications is well established. Not only do 
the atypical agents treat the positive symptoms of mental illness such as delusions and hallucinations, 
evidence is emerging that they may have additional benefits such as improving cognitive functioning 
and reducing negative symptoms and aggression. It is estimated that up to 80% of patients respond to 
these newer atypical medications and that relapse rates are significantly reduced. 
In the face of such optimistic information, a major concern is the rate of what might be termed 
sub-optimal adherence with treatment prescriptions. Estimates vary; however it is conservatively 
estimated that approximately 50% of people with psychotic disorders do not use their medications as 
prescribed. This is alarming although not unusual, with similar figures cited for other chronic health 
problems (Sawyer and Aroni, 2003). None the less, the impact of poor treatment adherence in people 
who have mental health problems has been well documented. For instance, Weiden and Olfson (1995) 
observe that when discharged patients stop their medication, relapse rates increased from about 3.4% 
per month to about 12% per month. Weiden and Olfson modelled known non-compliance rates and 
relapse rates on and off medication, reporting that over a 24-month period, optimal medication use 
alone can slow or eliminate over 25% of relapses. However, there remains a significant proportion of 
people for whom medication alone is insufficient to prevent relapse, and it is here that the value of 
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additional psychosocial interventions may is found. Wei den and Olfson estimate that medication 
non-compliance accounts for up to 40% of revolving door relapse and re-hospitalisations. 
Mental health clinician skills in managing non-adherence 
If optimal use of medication can reduce vulnerability to mental ill health, have community mental 
health workers been trained in skills to support medication use? The answer appears to be no. Coombs 
et al. (2003) recently undertook a study ofthe role of community mental health workers in supporting 
medication adherence. Primarily nurses, Coombs and colleagues found that 84% of respondents had 
received no formal training in medication adherence strategies. Ofthose who said that they had 
received training, they indicated that this had consisted of viewing lectures on pharmacology (an 
ineffective strategy given that enhanced clinician knowledge of psychopharmacology has been found 
not to predict improved patient medication adherence - Gray, 2001). Significantly, over 40% of 
Coombs sample reported they 'often' or 'always' had problems with issues such as discussing 
medication side effects, discussing the link between ceasing medication and becoming unwell, and 
undertaking education with the patient and family members about medication. Coombs also reported 
that the majority of his sample viewed the development of a therapeutic alliance as a 'low priority'. 
Clearly there is a need for both the enhancement of clinician skills and modification of therapeutic 
attitude as it relates to medication adherence. 
What skills to train for: strategies to enhance medication adherence 
Research into adherence interventions can be broadly divided into three categories: educational 
interventions; behavioural interventions; and cognitive behavioural interventions. Results suggest that 
only the cognitive behavioural approaches have demonstrated consistent improvements in adherence, 
with the seminal research conducted by Kemp and her colleagues (Kemp et aI., 1996/97/98). Kemp, a 
psychiatrist, developed an inpatient intervention termed 'Compliance Therapy'. 
Compliance Therapy is a manualised treatment program that incorporates motivational interviewing 
techniques and aspects of cognitive behavioural therapy. It introduced taking a therapeutic approach to 
solving difficulties with medication-taking by working collaboratively with the patient, emphasizing 
their choices and responsibilities, and focusing on their concerns about treatment. 
Most successful treatments that have followed, including Medication Alliance, have been modifications 
and enhancements of Kemp's original work. Kemp's study involved a randomized control trial with 
two inpatient groups - the Compliance Therapy group and a non-directive counselling group. Forty 
seven patients were seen by a psychiatrist and a psychologist for four to six sessions, each of an 
average of 40 minutes, and measures were taken at several time points. Kemp observed enhanced 
medication taking behaviour, and patients in the compliance therapy group took longer to relapse than 
the comparison group. 
However there were difficulties with Kemp's study. Kemp reported a minimal effect on levels of 
patient psychopathology (measured with the GAP) and there were methodological issues in the early 
phase of the study, with the assessor not blind to treatment condition. Given that her sample was an 
inpatient sample, there was also the potential for floor and ceiling effects, magnifying the clinical 
impact of her intervention but, more importantly, bringing into question the applicability of compliance 
therapy to a community setting. Finally, Kemp's intervention relied upon highly trained experts to 
deliver the therapy, limiting dissemination potential. 
In an effort to overcome the limitations of Kemp's compliance therapy, Gray and colleagues (2003) 
developed 'medication management '. Gray sought to demonstrate that the techniques of compliance 
therapy could be taught to 'coal face' clinicians in community mental health settings. Gray and 
colleagues describe a 10-day (80 hour) teaching program delivered across 10 weeks. The program 
involved training in assessment of medication adherence issues (such as patient attitudes to treatment, 
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insight into illness and medication side effects), cognitive and compliance therapy skills, 
psychopharmacology and ongoing (weekly) clinical supervision of the trainees' implementation of 
'medication management' (Gray et aI., 2003). It was Gray's contention that if the briefer 'medication 
management' training could effect significant changes in clinician skills and knowledge, then a more 
comprehensive clinical outcome trial would be justified. Gray found that his program was effective in 
enhancing both clinician skills and knowledge, demonstrating that at the very least, the techniques of 
compliance therapy were not restricted to experts in an inpatient setting. 
Training needs in Australia: the development of Medication Alliance 
It seems clear that optimal medication use is important, that mental health consumers commonly do not 
optimally use psychotropic medications and that, in Australia, community mental health workers are 
not trained in specific skills to enhance medication adherence. There also appears to be an established 
training program in Gray's 'medication management' that might meet that need. The question is, can 
medication management be imported into Australia? 
There are a number of challenges to the importation of Gray's program, as it stands, into an Australian 
context. Key among these are practical issues. Can the Australian mental health care system meet the 
costs associated with work release (80 hours) provided in the UK study? What are the implications for 
the dissemination of training to rural and remote sites and across different jurisdictions (and States)? 
There are also issues with respect to potential differences between populations. In the UK study, 50% 
of clients were receiving depot medication and only 20% of clients were prescribed atypical 
medication. In Australia some sites report up to 80% of clients are treated using atypicals (eg. Barwon 
Mental Health Service). Finally, Gray and colleagues failed to report on any attempt to manage or 
measure discrepant clinician attitudes, such as the low priority applied to the therapeutic alliance, as 
reported by Coombs et aI., (2003). 
In response to these issues, a team of clinicians and academics at the Illawarra Institute for Mental 
Health developed Medication Alliance (Byrne et aI., 2003). The development of Medication Alliance 
involved wide consultation with clinicians, patients, carers, and other researchers (including Gray and 
colleagues). Our review of the literature indicated that far from being of low importance, the 
development of the therapeutic alliance was a key strategic target in the provision of adherence 
interventions, a finding supported by patients and carers. Guided also by Health Behaviour theories, 
Medication Alliance surveyed the key features of successful adherence interventions (such as 
medication management and compliance therapy) and built upon these with a greater focus on the 
development of skills in the individualised assessment of patient need. Importantly, Medication 
Alliance was developed with the needs of Australian dissemination issues in mind, and the duration of 
the training was kept to a minimum. 
The final Medication Alliance 'therapy' approach integrated components of an adherence intervention 
into a standard evidence-based therapy approach. This included a process of engagement with the 
consumer, psychometric, clinical and functional analytic assessment of medication-taking behaviour, 
the delivery of targeted therapy for identified needs (such as motivational interviewing, CBT and 
problem solving), and evaluation of treatment outcomes. Added to this, Medication Alliance provides 
an opportunity to reflect upon duty of care obligations as they relate to assisting the patient to resolve 
medication issues and, where required, the use of more directive intervention strategies. 
Does it work? Outcomes of a Medication Alliance pilot study 
Following Gray et aI., (2003), we undertook a trial to determine to what extent Medication Alliance 
enhanced clinician skills and knowledge. In keeping with earlier observations, we added to our 
evaluation two measures of clinician attitudes as they relate to working with people who do not make 
optimum use of their medications. Training was provided to two groups of Tasmanian mental health 
workers (total 23 participants), with the duration of training being four days. Included in this time were 
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all data collection points. Total actual training time equated to a little over three days. The demographic 
characteristics of the health workers (Slide 19) indicated that our sample was mature and experienced, 
with relatively average caseloads. Furthermore the training was pertinent to their needs, with 70% of 
their caseload experiencing psychotic disorders and 35% reported as variable or unreliable in their use 
of medication. 
Outcome measures fell within three domains: knowledge, attitudes and skills (Slide 20). There were 
two knowledge measures. The first, the Medication Alliance Clinician Knowledge Questionnaire, is a 
15 item multiple-choice questionnaire that was developed by the Medication Alliance team to assess 
participant knowledge of material taught in the training program. The second knowledge measure, 
referred to as the Functional Analytic Case Formulation, is a case vignette detailing information for a 
person who has become unreliable in their medication use. The task is for the participant to identify the 
range of possible reasons for the change in adherence, and in particular, to identify the reasons that 
appear to be functionally related to the changed behaviour. 
Attitude scales included the Elsom Therapeutic Optimism Scale (ETOS) and the Medication Alliance 
Beliefs Questionnaire (MABQ). The ETOS was developed by Stephen Elsom at Monash University, 
initially for the Medication Alliance program. The ETOS measures the extent to which the participant 
feels optimistic about treatment outcomes for the people on their caseload. The MABQ surveys five 
constructs in relation to the participant's work with people whose adherence to medication is variable: 
motivation to work with them; adequacy of knowledge to work in the area; degree of expected work 
satisfaction when working with this type of patient; sense of self esteem as a result of this type of work; 
and perceived legitimacy to work in this area. 
Skills were measured via a blind rating of videotaped role-plays. The rating device, the Medication 
Alliance Cognitive Therapy Scale for Psychosis (MACTS-Psy) was an adapted version of the 
Cognitive Therapy Scale for Psychosis (Haddock et aI., 2001). The MACTS-Psy was specifically 
focused on a subset of behaviours taught and rehearsed in the training program. These were the 
participants' attempts at setting a therapy agenda, their ability to undertake an assessment ofthe 
'patient's' problem, their use of one or more therapy skills to resolve the problem, how well they 
supported the therapy with homework tasks, and the overall quality of the intervention. The quality of 
the intervention was rated according to evidence of engagement, assessment, therapy, evaluation ofthe 
session, proactive therapy approaches and demonstration of empathy. 
Our main analysis of the findings was by way of a series of paired samples t-tests. Although we had 
specific directional hypotheses, we chose 2-tailed p values with Bonferroni corrections to reduce the 
potential for Type 1 error. Analysis was conducted using SPSS Version 11.0. 
At the very least, we expected to find that by attending the workshop, participants' knowledge would 
be enhanced. This is precisely what we found (t = 4.27, p< .000), indicating that the participants' 
'factual' knowledge about adherence issues had been enhanced. However, we were more interested in 
how well the participants were able to apply that knowledge in order to understand an individual's 
reasons for non-adherence. This was measured by the functional analytic case formulation. We found 
that participants improved in their ability to identify both possible reasons for non adherence (t = 3.32, 
p< .003) as well as the specific causal variables (t = 2.73, p< .013). 
Likewise, we were able to demonstrate significant attitudinal change among participants. Given that 
clinician optimism has been associated with positive outcome expectancies by the patient, and 
following a Health Beliefs model in relation to adherence behaviour, we were keen to effect an 
improvement in participant optimism. This was achieved (t = 3.15, p< .005), with the greatest change 
occurring among those participants who were least optimistic to start with. However, results on the 
MABQ were less comprehensive, with improvements only observed in the participants' sense of 
adequacy oftheir knowledge in working with people who have medication non-adherence issues (t = 
4.43, p< .000) and the extent to which trainees expect to derive work satisfaction from engaging with 
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people who have medication non-adherence issues (t = 3.31, p< .003). 
The clinical domain assessed the extent to which participant skills were enhanced as a result of 
attending training. This represented a good point of comparison with the work of Gray et aI., (2003), 
given that their program was a 10 day program (versus the equivalent of 3 days in Medication Alliance) 
and that the Gray program was conducted over 10 weeks with weekly supervision and practice of skills. 
Ifwe were able to demonstrate skills enhancements, even across a limited array of skills variables, then 
we might conclude that the Medication Alliance program is a valid adherence-training program for the 
Australian health system. 
In an improvement on Gray's design, pre-training/post-training video role-plays were blind rated by 
two experienced therapists, enabling the determination of inter-rater reliabilities (Pearson r). Ofthe five 
skills, four were significantly enhanced. Agenda setting is an important skill in developing a 
collaborative framework with patients and in managing limited time. Participants significantly 
improved in their use of an agenda (t = 4.04, p< .001, r = .71). Medication Alliance provided skills 
based training in motivational interviewing, CBT techniques and problem solving skills, which were 
assessed in combined form as Total Intervention Skills. There was a significant improvement in total 
intervention skills (t = 5.23, p<'OOO, r = .72). The effective use of homework has been shown to be 
associated with enhanced treatment gain (Kazantzis and Deane, 1999) and was a specific focus of 
training in Medication Alliance. Participants demonstrated a significant improvement in their use of 
homework as a result oftraining (t = 4.19, p< .000, r = .56). Finally, the overall quality of the 
participants' intervention strategy was enhanced following training (t = 5.87, p< .000, r = .60). 
A limitation ofthe present study is the modest inter-rater reliability coefficients. One ofthe raters had 
to be replaced at short notice and the extent of rater training was unavoidably affected. For that reason 
the fifth skill, Problem Assessment, was deemed non-significant (t = 2.65, p<.015) with a Pearson's r 
of -.0 1. However, given that Medication Alliance training is significantly shorter than comparable (eg. 
Grayet aI., 2003) programs and that inter-rater reliabilities were calculated, we contend that these 
results are quite encouraging. 
Also encouraging were the positive ratings provided to the program by participants. The workshop 
evaluation questionnaire involved ten questions rated on a 1 - 7 Likert scale, with 7 indicating the most 
positive rating. There was also an opportunity for participants to make specific narrative comments on 
the training program. There was one participant outlier who consistently rated items negatively. We 
included the data ofthis person in all analyses, including the workshop evaluation. Not withstanding 
the relatively small sample size in this study, Medication Alliance was rated at about 517 and above 
across evaluation items (Slide 34). Given that the sample included experienced and well qualified 
clinicians, we contend that this is a clear endorsement from the field. Of particular note was the rating 
of 6.48 on the critical item 1 would recommend Medication Alliance training to other clinicians " 
providing a clear statement ofthe perceived utility of Medication Alliance training. 
Summary 
Medication Alliance training improves clinician skills, knowledge and attitudes in relation to working 
with patients who do not effectively use their medications. It represents an improvement upon previous 
similar programs in that it is focused on 'coal face' clinicians; it enhances attitudes and beliefs; and it is 
relatively brief. One key question remains however: does Medication Alliance training for clinicians 
result in clinical improvement for patients? Answering this question constitutes the next phase in the 
development of a Medication Alliance with consumers of mental health services. 
Postscript: Mental health services who may wish to participate in the clinical trial of Medication 
Alliance are invited to contact Mitch Byrne (mbyrne@uow.edu.au or + 6124221 5310). This is a 
staggered trial and sites will be included up to and including 2005. 
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